Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study

Improved therapeutic options are needed for patients with treatment-refractory nontuberculous mycobacterial lung disease caused by complex (MAC). To evaluate the efficacy and safety of daily amikacin liposome inhalation suspension (ALIS) added to standard guideline-based therapy (GBT) in patients wi...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of respiratory and critical care medicine Vol. 198; no. 12; pp. 1559 - 1569
Main Authors:	Griffith, David E., Eagle, Gina, Thomson, Rachel, Aksamit, Timothy R., Hasegawa, Naoki, Morimoto, Kozo, Addrizzo-Harris, Doreen J., O’Donnell, Anne E., Marras, Theodore K., Flume, Patrick A., Loebinger, Michael R., Morgan, Lucy, Codecasa, Luigi R., Hill, Adam T., Ruoss, Stephen J., Yim, Jae-Joon, Ringshausen, Felix C., Field, Stephen K., Philley, Julie V., Wallace, Richard J., van Ingen, Jakko, Coulter, Chris, Nezamis, James, Winthrop, Kevin L.
Format:	Journal Article
Language:	English
Published:	United States American Thoracic Society 15.12.2018
Subjects:	Administration, Inhalation Amikacin - administration & dosage Amikacin - therapeutic use Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - therapeutic use Antibiotics Bacteriology Chronic obstructive pulmonary disease Confidence intervals Female Humans Infectious diseases Life Sciences Liposomes Lung diseases Lung Diseases - drug therapy Lung Diseases - microbiology Male Microbiology and Parasitology Middle Aged Mycobacterium avium Complex Mycobacterium avium-intracellulare Infection - drug therapy Prospective Studies Treatment Outcome Tuberculosis Australia Europe nontuberculous mycobacteria liposomal amikacin for inhalation ALIS culture conversion guideline-based therapy
ISSN:	1073-449X, 1535-4970, 1535-4970
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!